Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.82 +2.55%
Revenue Growth %: -33.6%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -33.6%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- AutoZone beats profit view but misses on revenue
- FactSet acquires BCC Group to expand real-time market data platform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
